Boehringer Ingelheim Phase III clinical trial found that empagliflozin in combination with metformin reduces blood glucose levels in adults with type 2 diabetes

Published 8, June 2015 at 132 × 172 in Boehringer Ingelheim: Phase III clinical trial found that empagliflozin in combination with metformin reduces blood glucose levels in adults with type 2 diabetes

Professor Hans-J. Woerle, Vice President, Head of Medicine, Therapeutic Area Metabolism, Boehringer Ingelheim

Professor Hans-J. Woerle, Vice President, Head of Medicine, Therapeutic Area Metabolism, Boehringer Ingelheim

Bookmark the permalink.

Comments are closed.